tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics price target lowered to $54 from $63 at Leerink
The FlyArcturus Therapeutics price target lowered to $54 from $63 at Leerink
2d ago
ARCT
Arcturus Therapeutics: Promising Prospects with ARCT-032 and Billion-Dollar Market Potential
PremiumRatings
Arcturus Therapeutics: Promising Prospects with ARCT-032 and Billion-Dollar Market Potential
2d ago
ARCT
Positive Outlook and Buy Rating for Arcturus Therapeutics Amid Promising Pipeline Developments and Strong Financial Position
PremiumRatings
Positive Outlook and Buy Rating for Arcturus Therapeutics Amid Promising Pipeline Developments and Strong Financial Position
9d ago
ARCT
Arcturus Therapeutics: Promising Developments and Strong Financial Health Justify Buy Rating
PremiumRatings
Arcturus Therapeutics: Promising Developments and Strong Financial Health Justify Buy Rating
11d ago
ARCT
Arcturus Therapeutics price target raised to $49 from $47 at Citi
PremiumThe Fly
Arcturus Therapeutics price target raised to $49 from $47 at Citi
12d ago
ARCT
Arcturus Therapeutics price target lowered to $42 from $45 at Wells Fargo
PremiumThe FlyArcturus Therapeutics price target lowered to $42 from $45 at Wells Fargo
12d ago
ARCT
Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs
Premium
Ratings
Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs
12d ago
ARCT
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress
Premium
Company Announcements
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress
12d ago
ARCT
Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
PremiumThe Fly
Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
13d ago
ARCT
Is ARCT a Buy, Before Earnings?
PremiumPre-Earnings
Is ARCT a Buy, Before Earnings?
15d ago
ARCT
Private Markets: Canva draws attention as IPO candidate following Figma debut
PremiumThe Fly
Private Markets: Canva draws attention as IPO candidate following Figma debut
16d ago
BA
CAI
Arcturus Therapeutics: Strategic Focus Beyond mRNA Vaccines Drives Buy Rating
PremiumRatings
Arcturus Therapeutics: Strategic Focus Beyond mRNA Vaccines Drives Buy Rating
17d ago
ARCT
Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating
PremiumRatingsArcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating
1M ago
ARCT
3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 7/7/2025, According to Top Analysts
2M ago
FC
ARCT
Arcturus Therapeutics price target raised to $35 from $32 at Scotiabank
Premium
The Fly
Arcturus Therapeutics price target raised to $35 from $32 at Scotiabank
2M ago
ARCT
Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating
PremiumRatings
Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating
2M ago
ARCT
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
PremiumRatings
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
2M ago
ARCT
Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs
PremiumRatings
Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs
2M ago
ARCT
Citi adds ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
PremiumThe Fly
Citi adds ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
2M ago
ARCT
Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
PremiumRatingsArcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
2M ago
ARCT
Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
Premium
Ratings
Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
2M ago
ARCT
Arcturus Therapeutics Announces Positive Phase 2 Results
Premium
Company Announcements
Arcturus Therapeutics Announces Positive Phase 2 Results
2M ago
8K
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >